tetano
Editor, Senior Moderator
IJID Reg
. 2023 Jun;7:222-229.
doi: 10.1016/j.ijregi.2023.04.003. Epub 2023 Apr 6. Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study
Gustavo Jardim Volpe[SUP] 1 [/SUP], Sandra Coccuzzo Sampaio Vessoni[SUP] 2 [/SUP], Lais Braga Soares[SUP] 3 [/SUP], Maria Aparecida Alves Leite Dos Santos Almeida[SUP] 3 [/SUP], Patrícia Emília Braga[SUP] 3 [/SUP], Glenda Renata de Moraes[SUP] 4 [/SUP], Natasha Nicos Ferreira[SUP] 1 [/SUP], Pedro Manoel Marques Garibaldi[SUP] 1 [/SUP], Simone Kashima[SUP] 5 [/SUP], Benedito Antônio Lopes Fonseca[SUP] 5 [/SUP], Rodrigo Tocantins Calado[SUP] 5 [/SUP], Hugo Alberto Brango García[SUP] 6 [/SUP], João Italo Dias de França[SUP] 3 [/SUP], Marcos Alves de Lima[SUP] 3 [/SUP], Pedro Henrique de Mesquita Pacheco[SUP] 3 [/SUP], Marcos Carvalho Borges[SUP] 1 5 [/SUP], Dimas Tadeu Covas[SUP] 2 [/SUP]
Affiliations
Background: The long-term humoral immune response after vaccination varies between vaccines and is dependent on the accuracy of the antibody test. A better understanding of the vaccine immune response may help to define vaccination strategies against coronavirus disease 2019 (COVID-19).
Objective: To investigate the long-term immunological response to CoronaVac vaccine and determinants of breakthrough COVID-19 infection.
Methods: A long-term, prospective cohort study involving vaccinated adult and elderly subjects was conducted to investigate the presence of anti-RBD-specific immunoglobulin (Ig)G, anti-nucleocapsid IgG and anti-spike trimeric protein IgG. Antibody level dynamics and risk factors associated with breakthrough COVID-19 infection were investigated.
Results: In total, 3902 participants were included in this study. Vaccination with two doses of CoronaVac and a booster dose increased the levels of anti-RBD-specific IgG, anti-nucleocapsid IgG and anti-spike trimeric IgG significantly. In adults, anti-nucleocapsid IgG and anti-spike trimeric IgG levels decreased significantly 7 months after the second dose. In adults and the elderly, the levels of anti-spike trimeric IgG and anti-RBD IgG decreased significantly 4 and 6 months after the booster dose, respectively. Previous exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and anti-spike trimeric IgG titres was independently associated with a lower probability of post-vaccination infection.
Conclusions: A significant increase in antibody levels was found after two doses of CoronaVac and a booster dose. Antibody titres declined significantly 7 months post-vaccination in participants who did not receive a booster dose. Higher levels of antibodies and previous SARS-CoV-2 infection were associated with protection against breakthrough COVID-19.
Keywords: COVID-19; COVID-19 vaccine booster shot; CoronaVac vaccine; Humoral; Immunity.
. 2023 Jun;7:222-229.
doi: 10.1016/j.ijregi.2023.04.003. Epub 2023 Apr 6. Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study
Gustavo Jardim Volpe[SUP] 1 [/SUP], Sandra Coccuzzo Sampaio Vessoni[SUP] 2 [/SUP], Lais Braga Soares[SUP] 3 [/SUP], Maria Aparecida Alves Leite Dos Santos Almeida[SUP] 3 [/SUP], Patrícia Emília Braga[SUP] 3 [/SUP], Glenda Renata de Moraes[SUP] 4 [/SUP], Natasha Nicos Ferreira[SUP] 1 [/SUP], Pedro Manoel Marques Garibaldi[SUP] 1 [/SUP], Simone Kashima[SUP] 5 [/SUP], Benedito Antônio Lopes Fonseca[SUP] 5 [/SUP], Rodrigo Tocantins Calado[SUP] 5 [/SUP], Hugo Alberto Brango García[SUP] 6 [/SUP], João Italo Dias de França[SUP] 3 [/SUP], Marcos Alves de Lima[SUP] 3 [/SUP], Pedro Henrique de Mesquita Pacheco[SUP] 3 [/SUP], Marcos Carvalho Borges[SUP] 1 5 [/SUP], Dimas Tadeu Covas[SUP] 2 [/SUP]
Affiliations
- PMID: 37102137
- PMCID: PMC10076246
- DOI: 10.1016/j.ijregi.2023.04.003
Background: The long-term humoral immune response after vaccination varies between vaccines and is dependent on the accuracy of the antibody test. A better understanding of the vaccine immune response may help to define vaccination strategies against coronavirus disease 2019 (COVID-19).
Objective: To investigate the long-term immunological response to CoronaVac vaccine and determinants of breakthrough COVID-19 infection.
Methods: A long-term, prospective cohort study involving vaccinated adult and elderly subjects was conducted to investigate the presence of anti-RBD-specific immunoglobulin (Ig)G, anti-nucleocapsid IgG and anti-spike trimeric protein IgG. Antibody level dynamics and risk factors associated with breakthrough COVID-19 infection were investigated.
Results: In total, 3902 participants were included in this study. Vaccination with two doses of CoronaVac and a booster dose increased the levels of anti-RBD-specific IgG, anti-nucleocapsid IgG and anti-spike trimeric IgG significantly. In adults, anti-nucleocapsid IgG and anti-spike trimeric IgG levels decreased significantly 7 months after the second dose. In adults and the elderly, the levels of anti-spike trimeric IgG and anti-RBD IgG decreased significantly 4 and 6 months after the booster dose, respectively. Previous exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and anti-spike trimeric IgG titres was independently associated with a lower probability of post-vaccination infection.
Conclusions: A significant increase in antibody levels was found after two doses of CoronaVac and a booster dose. Antibody titres declined significantly 7 months post-vaccination in participants who did not receive a booster dose. Higher levels of antibodies and previous SARS-CoV-2 infection were associated with protection against breakthrough COVID-19.
Keywords: COVID-19; COVID-19 vaccine booster shot; CoronaVac vaccine; Humoral; Immunity.